2021
DOI: 10.3390/jcm10184141
|View full text |Cite
|
Sign up to set email alerts
|

Potentially Detrimental Effects of Hyperosmolality in Patients Treated for Traumatic Brain Injury

Abstract: Hyperosmotic therapy is commonly used to treat intracranial hypertension in traumatic brain injury patients. Unfortunately, hyperosmolality also affects other organs. An increase in plasma osmolality may impair kidney, cardiac, and immune function, and increase blood–brain barrier permeability. These effects are related not only to the type of hyperosmotic agents, but also to the level of hyperosmolality. The commonly recommended osmolality of 320 mOsm/kg H2O seems to be the maximum level, although an increase… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 90 publications
0
6
0
Order By: Relevance
“…In humans, cerebral edema resulting from brain injury is frequently treated with hyperosmotic therapy to relieve inter cranial hypertension [32]. However, recent evidence suggests that elevating plasma osmolality can also lead to increased QTc and a higher risk of cardiac arrhythmias [33,34]. We therefore sought to determine what effect osmotic perturbations had on zebrafish ECG patterns.…”
Section: Resultsmentioning
confidence: 99%
“…In humans, cerebral edema resulting from brain injury is frequently treated with hyperosmotic therapy to relieve inter cranial hypertension [32]. However, recent evidence suggests that elevating plasma osmolality can also lead to increased QTc and a higher risk of cardiac arrhythmias [33,34]. We therefore sought to determine what effect osmotic perturbations had on zebrafish ECG patterns.…”
Section: Resultsmentioning
confidence: 99%
“…In summary, the neuroendocrine pathway, including the central nervous autonomous system and the endocrine system, and the inflammatory and immune responses play a major role in its development [ 5 , 6 ]. Patient-, trauma-, iatrogenic- or treatment-related factors may contribute [ 5 , 6 , 7 ]. Indeed, the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) showed that an AKI incidence of 12% of cases in a sample of 1262 TBI patients was associated with patients’ previous conditions (renal history and insulin-dependent diabetes), trauma (pupillary reactivity) and treatments received (osmotic therapy and natremia ≥ 150 mmol/L in the initial 3 days after injury) [ 8 ].…”
Section: Discussionmentioning
confidence: 99%
“…Iatrogenic factors, including exposure to radiocontrast agents, nephrotoxic antibiotics and anti-inflammatory agents [ 6 ], must also be considered in brain-injured patients. The treatment of intracranial hypertension may also contribute to the development of AKI [ 7 ].…”
Section: Introductionmentioning
confidence: 99%
“…Current interventions include the use of drugs such as mannitol or bradykinin analog (Cereport/RMP7) to induce disruption of barrier function. Hypertonic mannitol, reduces tight junction integrity through endothelial cell contraction ( Dabrowski et al, 2021 ), but its limitation is that it may cause seizures ( Marchi et al, 2007 ). Cereport/RMP-7 has shown some potential to transiently increase BBB permeability ( Borlongan and Emerich, 2003 ) and has shown some efficacy in animal models for the treatment of CNS pathology, but has not yielded satisfactory results in clinical trials ( Prados et al, 2003 ).…”
Section: Prospects For Improving Drug Delivery Within the Cnsmentioning
confidence: 99%